These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7848668)

  • 1. Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group.
    Glassroth J; Jordan M; Wallace JM; Kvale PA; Follmann DA; Rosen MJ; Reichman LB; Mossar M; Hopewell PC
    Am J Prev Med; 1994; 10(5):259-66. PubMed ID: 7848668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis and treatment of Pneumocystis carinii pneumonia.
    O'Doherty MJ; Bateman NT
    Br J Hosp Med; 1991 May; 45(5):277-8, 280, 283. PubMed ID: 1676607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
    Hirschtick RE; Glassroth J; Jordan MC; Wilcosky TC; Wallace JM; Kvale PA; Markowitz N; Rosen MJ; Mangura BT; Hopewell PC
    N Engl J Med; 1995 Sep; 333(13):845-51. PubMed ID: 7651475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis carinii pneumonia prophylaxis during pregnancy.
    Connelly RT; Lourwood DL
    Pharmacotherapy; 1994; 14(4):424-9. PubMed ID: 7937279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of viral hepatitis and infectious complications among human immunodeficiency virus-infected injection drug users at a referral hospital.
    Liang SH; Lo YC; Lin HH; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2008 Jun; 41(3):200-8. PubMed ID: 18629414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV diagnoses among injection-drug users in states with HIV surveillance--25 states, 1994-2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Jul; 52(27):634-6. PubMed ID: 12855944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
    Shah SN; Smith EE; Obonyo CO; Kain KC; Bloland PB; Slutsker L; Hamel MJ
    J Infect Dis; 2006 Dec; 194(11):1519-28. PubMed ID: 17083036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive care among HIV-positive patients in a general medicine practice.
    Gifford AL; McPhee SJ; Fordham D
    Am J Prev Med; 1994; 10(1):5-9. PubMed ID: 7909673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outreach-based HIV prevention for injecting drug users: a review of published outcome data.
    Coyle SL; Needle RH; Normand J
    Public Health Rep; 1998 Jun; 113 Suppl 1(Suppl 1):19-30. PubMed ID: 9722807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incidence of bacterial pneumonia in HIV-positive patients treated with preventive co-trimoxazole or pentamidine].
    Koch A; Kothe H; Braun J; Kämmerer R; Friedrich HJ; Dalhoff K
    Pneumologie; 1998 Nov; 52(11):614-21. PubMed ID: 9885511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members.
    Malamba SS; Mermin J; Reingold A; Lule JR; Downing R; Ransom R; Kigozi A; Hunt BM; Hubbard A; Rosenthal PJ; Dorsey G
    Am J Trop Med Hyg; 2006 Sep; 75(3):375-80. PubMed ID: 16968909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis of AIDS-related opportunistic infections (OIs).
    Hardy WD
    AIDS Clin Rev; 1989; ():125-50. PubMed ID: 2562216
    [No Abstract]   [Full Text] [Related]  

  • 19. Trends in human immunodeficiency virus infection among drug users in a detoxification unit.
    Muga R; Sanvisens A; Egea JM; Tor J; Rey-Joly C
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S404-9. PubMed ID: 14648455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.